Hoba, a Danish biotech from Novo, raises $25M to crack into difficult pain and hearing loss fields
Novo Holdings-founded biotech Hoba Therapeutics has raised $25 million in the first close of a Series A financing to bankroll its investigational medicines for pain and hearing loss.
Copenhagen-based Hoba, which got its start about seven years ago after acquiring IP from NeuroSearch spinoff NsGene, has a non-opioid candidate that it hopes could follow in the footsteps of Vertex Pharmaceuticals’ leading program. Boston-based Vertex is on the verge of a late-stage readout for its candidate VX-548 for acute pain.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.